Administration schedules of PEG-rHuMGDF following BMT in mice. Subcutaneous administration schedules of PEG-rHuMGDF were shown as follows: (1) consecutive treatment at a dose of 30 g/kg/day from the day after BMT (day 1) for 13 consecutive days ( ); (2) alternate-day treatment at a dose of 55.7 g/kg/day on days 1, 3, 5, 7, 9, 11 and 13 (`); and (3) at an interval of 3 days at a dose of 78 g/kg/day on days 1, 5, 9 and 13 ( ). The same volume of vehicle solution was injected as control from the day after BMT for 13 consecutive days ( ). Each bar indicates the mean Ϯ s.e. of five to six mice. Significant differences (*P Ͻ 0.05, **P Ͻ 0.01) compared with the vehicle-treated mice were tested by Dunnett's test.
In Figures 3 and 4 of the above paper some additional asterisks appeared in the final published copy of the paper. Corrected versions of the figures follow. (1) consecutive treatment at a dose of 30 g/kg/day from the day after BMT (day 1) for 13 consecutive days ( ); (2) alternate-day treatment at a dose of 55.7 g/kg/day on days 1, 3, 5, 7, 9, 11 and 13 (`); and (3) at an interval of 3 days at a dose of 78 g/kg/day on days 1, 5, 9 and 13 ( ). The same volume of vehicle solution was injected as control from the day after BMT for 13 consecutive days ( ). Each bar indicates the mean Ϯ s.e. of five to six mice. Significant differences (*P Ͻ 0.05, **P Ͻ 0.01) compared with the vehicle-treated mice were tested by Dunnett's test. 
